Orion Corp New B Shs (ORINF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Orion's earnings conference call and webcast for the financial period of January-September 2025. My name is Tuukka Hirmonen. I'm the head of investor relations here at Orion. In a few moments, we will start with the presentation by our CEO and president, Mrs. Liisa Hurme. After which then we will have Q&A session where you can pose questions both to Liisa and also to our CFO René Lindell. We will be first taking questions from the conference call lines and after that we will turn to the webcast questions so you can type in your questions using the chat box in the webcast view in the bottom. And just before I let Liisa to take the stage, I'd like to draw your attention to this disclaimer regarding forward-looking statements. But with that, it's my pleasure to hand over to Liisa. Liisa. Thank you, Tuukka. And welcome to Orion Q3 webcast on my behalf as well. Here are some highlights from Q3 2025. Nubeca received approval from the European Commission for use of darolutamide and ADT, androgen deprivation therapy, in patients with metastatic hormone sensitive prostate cancer. Nubeca also reached all-time high royalties and product deliveries to Bayer during Q3. Generics and consumer health business had a strong quarter, supported by good availability of products in our major markets and very successful new launches. Unfortunately, ODI 105, Tasipimidine, phase 2 trial for insomnia didn't reach its efficacy target. And we decided to discontinue the development of that program. And Q3 financials are here. And before I go here deeper into the financials, it is good to remember that the comparative period Q3 2024 was an exceptional quarter. We received 130 million worth of milestones last year's Q3. There was a 70 million sales milestone from Baye...